In turn, a significant decrease in circulating eNAMPT levels could be observed in some RA studies following treatment with conventional synthetic disease modifying antirheumatic drugs (csDMARDs) (170), TNF-α blockers (195), anti-CD20 antibody (172), or with a combination of methotrexate and anti-IL-6 therapy (196). Here, IL6 is linked to rheumatoid arthritis.